Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 3 |
2008 | 2 |
2015 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism.
Hum Gene Ther. 2006 Mar;17(3):353-61. doi: 10.1089/hum.2006.17.353.
Hum Gene Ther. 2006.
PMID: 16544984
Estrogen plays a critical role in AAV2-mediated gene transfer in ovarian cancer.
Shi WF, Bartlett JS.
Shi WF, et al.
Acta Pharmacol Sin. 2008 Dec;29(12):1440-50. doi: 10.1111/j.1745-7254.2008.00894.x.
Acta Pharmacol Sin. 2008.
PMID: 19026163
Item in Clipboard
Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery.
Davis AS, Federici T, Ray WC, Boulis NM, OʼConnor D, Clark KR, Bartlett JS.
Davis AS, et al.
Neurosurgery. 2015 Feb;76(2):216-25; discussion 225. doi: 10.1227/NEU.0000000000000589.
Neurosurgery. 2015.
PMID: 25549186
Item in Clipboard
Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes.
Arnold GS, Sasser AK, Stachler MD, Bartlett JS.
Arnold GS, et al.
Mol Ther. 2006 Jul;14(1):97-106. doi: 10.1016/j.ymthe.2006.02.014. Epub 2006 Apr 19.
Mol Ther. 2006.
PMID: 16624620
Free article.
Item in Clipboard
Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase.
Stachler MD, Chen I, Ting AY, Bartlett JS.
Stachler MD, et al.
Mol Ther. 2008 Aug;16(8):1467-73. doi: 10.1038/mt.2008.129. Epub 2008 Jun 17.
Mol Ther. 2008.
PMID: 18560418
Free article.
Item in Clipboard
Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma.
Shi W, Hemminki A, Bartlett JS.
Shi W, et al.
Gynecol Oncol. 2006 Dec;103(3):1054-62. doi: 10.1016/j.ygyno.2006.06.020. Epub 2006 Jul 25.
Gynecol Oncol. 2006.
PMID: 16870238
Item in Clipboard
Cite
Cite